Telaprevir

Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir

WALTHAM, Mass., Aug. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on profiles provided to them of emerging protease inhibitors, surveyed physicians indicate that they will prescr...

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company

... potential milestone payments, from the sale of commercialization rights of telaprevir in Japan and other countries in the Far East to Mitsubishi Tanabe Pharma Co...uncing its intention to sell certain future European milestone payments for telaprevir aggregating $250 million earlier in July and raising approximately $314 mil...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...ring's Next-Generation Protease Inhibitor II-6 telaprevir (VX-950) - The Most Promising Pipeline HCV Pro...I Class Lead Candidate II-7 Comparison Between telaprevir and Boceprevir II-7 telaprevir and Boceprevir - A Comparison II-8 Polymerase ...

Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013

...drug developers. Several agents in late-stage development -- most notably protease inhibitors such as Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Schering-Plough's boceprevir as well as polymerase inhibitors such as Roche/Pharmasset's R-7128 and Pfizer's filibuvir -- will drive market growth...

Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)

... alone, there is certainly valid justification for telaprevir to be considered the lead adjunct drug candidate b...community. This is reinforced by the reality that telaprevir represents a significant value component of Vertex... HCV market coverage, reports the following on the telaprevir clinical outcome; "The data keeps Telarevir ahead ...

NEJM study points to new era in hepatitis C treatment

...of a hepatitis Cspecific protease inhibitor called telaprevir to the current standard therapy can significantly ...ill Cornell Medical College. "Not only does adding telaprevir make standard hepatitis C treatment more effective...ion of therapy. They compared a 12-week regimen of telaprevir combined with two different durations of the stand...

AGA Institute presents cutting-edge research during DDW

...sults of PROVE3, a Phase 2b Clinical Trial Assessing Safety and Efficacy of telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-response, Viral ...t with pegylated interferon and ribavirin (patients received treatment with telaprevir combined with pegylated interferon and ribavirin). Another abstract wil...

New Treatment Combo Better Against Hepatitis C

... Adding antiviral telaprevir increases cure rate, studies show,,,, ...l 29 (HealthDay News) -- Adding the antiviral drug telaprevir to standard treatment for hepatitis C increases th...aged to cure significantly more patients by adding telaprevir to standard care," McHutchison said. "We cured 50 ...

In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response

... telaprevir in Combination with a Long-Acting Interferon and R...f Vertex/Janssen Pharmaceutica/Mitsubishi Tanabe's telaprevir or Schering-Plough's boceprevir to peginterferon/r...osing. Based on available data and expert opinion, telaprevir plus ribavirin and a long-acting interferon will e...

Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)

...od Defendants misled investors by making materially false and misleading statements concerning the development of Vertex's new HCV protease inhibitor: telaprevir or VX-950. Ultimately, Vertex intends to use the inhibitor in a new drug targeted at the treatment of hepatitis C. Among other things, the Complaint a...

Telaprevir in Medical Technology

Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)

BARCELONA, Spain--(BUSINESS WIRE)--Apr 11, 2007 - New data supporting the clinical development of telaprevir (VX-950), one of the most advanced investigational oral protease inhibitors for the treatment of hepatitis C virus (HCV) infection, will be presented at the 42nd Annual Meeting of the Europe...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to eval...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...g that combinations of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These st...istant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir and PSI-6130. About ANA598 Anadys retains worldwide rights to ANA5...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...show ANA598 to be synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agen...istant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir (VX-950) and PSI-6130. Data will also be presented demonstrating synergy be...

Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

...e the Company failed to indicate the findings of PROVE 2 during the Class Period, when the results became known. The Company had touted the results of telaprevir in PROVE 1, which showed patient improvement at 16% as compared to the control group. However, patients in PROVE 2 displayed results that were only 6%...

Telaprevir in Biological Technology

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

...g that combinations of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These st...istant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir and PSI-6130. ANA773 ANA773 is an oral prodrug...

Biotech Hall of Fame Inductees Announced

...lood vessels to support cancer cell growth). Vertex Pharmaceuticals The Company is leading the development of the HCV protease inhibitor, telaprevir (VX-950), and in 2007 is conducting a broad Phase 2 clinical program of this drug candidate. Vertex is also focused on the development of VX...